Accelerate Diagnostics, Inc. – NASDAQ:AXDX
Accelerate Diagnostics stock price today
$0.034
-1.06
-96.91%
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 2 days
Accelerate Diagnostics stock price monthly change
-4.35%
month
Accelerate Diagnostics stock price quarterly change
-4.35%
quarter
Accelerate Diagnostics stock price yearly change
-73.68%
year
Accelerate Diagnostics key metrics
Market Cap | 28.80M |
Enterprise value | 98.05M |
P/E | -0.8 |
EV/Sales | 7.47 |
EV/EBITDA | -1.57 |
Price/Sales | 4.54 |
Price/Book | -2.68 |
PEG ratio | -0.04 |
EPS | -3.92 |
Revenue | 12.14M |
EBITDA | -41.96M |
Income | -52.3M |
Revenue Q/Q | 3.87% |
Revenue Y/Y | -3.68% |
Profit margin | -537.24% |
Oper. margin | -518.72% |
Gross margin | -5.08% |
EBIT margin | -518.72% |
EBITDA margin | -345.68% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAccelerate Diagnostics stock price history
Accelerate Diagnostics stock forecast
Accelerate Diagnostics financial statements
| Jun 2023 | 2.92M | -25.98M | -889.42% |
|---|---|---|---|
| Sep 2023 | 3.29M | 910K | 27.58% |
| Dec 2023 | 3M | -13M | -433.33% |
| Mar 2024 | 2.92M | -14.23M | -487.16% |
| Sep 2025 | 4.30M | -4.49M | -104.33% |
|---|---|---|---|
| Oct 2025 | 4.30M | -5.86M | -136.31% |
| Dec 2025 | 6.2M | -4.94M | -79.81% |
| Dec 2025 | 4.49M | -5.75M | -128.1% |
Analysts Price target
Financials & Ratios estimates
| Jun 2023 | 49878000 | 88.54M | 177.52% |
|---|---|---|---|
| Sep 2023 | 39324000 | 74.35M | 189.09% |
| Dec 2023 | 31366000 | 51.25M | 163.41% |
| Mar 2024 | 30722000 | 56.50M | 183.91% |
| Jun 2023 | -10.82M | 915K | 9.80M |
|---|---|---|---|
| Sep 2023 | -8.25M | -354K | -817K |
| Dec 2023 | -7.75M | -110K | 107K |
| Mar 2024 | -8.45M | -513K | 11.43M |
Accelerate Diagnostics alternative data
| Aug 2023 | 179 |
|---|---|
| Sep 2023 | 179 |
| Oct 2023 | 179 |
| Nov 2023 | 179 |
| Dec 2023 | 179 |
| Jan 2024 | 179 |
| Feb 2024 | 179 |
| Mar 2024 | 179 |
| Apr 2024 | 179 |
| May 2024 | 134 |
| Jun 2024 | 134 |
| Jul 2024 | 134 |
Accelerate Diagnostics other data
34.02%
+6.42%
of AXDX is owned by hedge funds
25.93M
+7.23M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Jan 2024 | 293330 | 0 |
| Feb 2024 | 0 | 844 |
| Apr 2024 | 0 | 97425 |
| May 2024 | 0 | 361 |
| Dec 2024 | 200000 | 200000 |
| Quarter | Transcript |
|---|---|
| Q1 2024 8 May 2024 | Q1 2024 Earnings Call Transcript |
| Q4 2023 28 Mar 2024 | Q4 2023 Earnings Call Transcript |
| Q3 2023 9 Nov 2023 | Q3 2023 Earnings Call Transcript |
| Q2 2023 10 Aug 2023 | Q2 2023 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Jack Phillips (1966) Chief Executive Officer, Pres & Director | $619,960 |
Mr. Steve Reichling (1978) Chief Financial Officer, Chief Accounting Officer & Sec. | $324,080 |
| Mr. Lawrence Mehren (1966) Advisor | $293,270 |
| Mr. Ron Price (1964) Chief Commercial Officer of Americas | $225,230 |
-
What's the price of Accelerate Diagnostics stock today?
One share of Accelerate Diagnostics stock can currently be purchased for approximately $0.03.
-
When is Accelerate Diagnostics's next earnings date?
Unfortunately, Accelerate Diagnostics's (AXDX) next earnings date is currently unknown.
-
Does Accelerate Diagnostics pay dividends?
No, Accelerate Diagnostics does not pay dividends.
-
How much money does Accelerate Diagnostics make?
Accelerate Diagnostics has a market capitalization of 28.80M and it's past years’ income statements indicate that its last revenue has decreased compared to the previous period by 5.43% to 12.06M US dollars.
-
What is Accelerate Diagnostics's stock symbol?
Accelerate Diagnostics, Inc. is traded on the NASDAQ under the ticker symbol "AXDX".
-
What is Accelerate Diagnostics's primary industry?
Company operates in the Healthcare sector and Medical - Devices industry.
-
How do i buy shares of Accelerate Diagnostics?
Shares of Accelerate Diagnostics can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are Accelerate Diagnostics's key executives?
Accelerate Diagnostics's management team includes the following people:
- Mr. Jack Phillips Chief Executive Officer, Pres & Director(age: 59, pay: $619,960)
- Mr. Steve Reichling Chief Financial Officer, Chief Accounting Officer & Sec.(age: 47, pay: $324,080)
- Mr. Lawrence Mehren Advisor(age: 59, pay: $293,270)
- Mr. Ron Price Chief Commercial Officer of Americas(age: 61, pay: $225,230)
-
How many employees does Accelerate Diagnostics have?
As Jul 2024, Accelerate Diagnostics employs 134 workers, which is 25% less then previous quarter.
-
When Accelerate Diagnostics went public?
Accelerate Diagnostics, Inc. is publicly traded company for more then 31 years since IPO on 7 Apr 1994.
-
What is Accelerate Diagnostics's official website?
The official website for Accelerate Diagnostics is acceleratediagnostics.com.
-
Where are Accelerate Diagnostics's headquarters?
Accelerate Diagnostics is headquartered at 3950 South Country Club Road, Tucson, AZ.
-
How can i contact Accelerate Diagnostics?
Accelerate Diagnostics's mailing address is 3950 South Country Club Road, Tucson, AZ and company can be reached via phone at +52 03653100.
Accelerate Diagnostics company profile:
Accelerate Diagnostics, Inc.
acceleratediagnostics.comExchange:
NASDAQ
Full time employees:
134
Industry:
Medical - Devices
Sector:
Healthcare
Accelerate Diagnostics, Inc., an in vitro diagnostics company, provides solutions for the diagnosis of serious infections in the United States, Europe, and the Middle East. The company offers Accelerate Pheno system, an in vitro diagnostic platform for the identification and antibiotic susceptibility testing of pathogens associated with serious or health care-associated infections, including gram-positive and gram-negative organisms. It also provides the Accelerate PhenoTest, a test kit for the system, which provides identify and antibiotic susceptibility testing results for patients suspected of bacteremia or fungemia, both life-threatening conditions with high morbidity and mortality risk. The company was formerly known as Accelr8 Technology Corporation and changed its name to Accelerate Diagnostics, Inc. in December 2012. Accelerate Diagnostics, Inc. was incorporated in 1982 and is headquartered in Tucson, Arizona.
3950 South Country Club Road
Tucson, AZ 85714
Tucson, AZ 85714
CIK: 0000727207
ISIN: US00430H2013
CUSIP: 00430H102
